New Two-Pronged immune drug joins fight against tough ovarian cancers
NCT ID NCT07432594
Summary
This study is testing if adding a new immune-boosting drug (Aitua) to standard chemotherapy helps patients with advanced ovarian cancer. The goal is to shrink tumors better before surgery, allowing surgeons to remove all visible cancer. About 82 patients will be randomly assigned to receive either the standard chemo or the chemo plus the new drug for three cycles before their operation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.